Martin Hoyle

Summary

Affiliation: Peninsula Medical School
Country: UK

Publications

  1. ncbi request reprint Future drug prices and cost-effectiveness analyses
    Martin Hoyle
    Peninsula Medical School, Peninsula Technology Assessment Group PenTAG, Universities of Plymouth and Exeter, Exeter, UK
    Pharmacoeconomics 26:589-602. 2008
  2. doi request reprint Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Medical School, University of Exeter, Exeter, UK
    Value Health 16:288-96. 2013
  3. doi request reprint Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia
    Martin Hoyle
    Peninsular College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom
    Value Health 14:1057-67. 2011
  4. doi request reprint Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
    M Hoyle
    PenTAG, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth, UK
    Health Technol Assess 15:61-7. 2011
  5. pmc Improved curve fits to summary survival data: application to economic evaluation of health technologies
    Martin W Hoyle
    Peninsula College of Medicine and Dentistry, Veysey Building, Salmon Pool Lane, Exeter, EX2 4SG, UK
    BMC Med Res Methodol 11:139. 2011
  6. doi request reprint Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis
    Martin Hoyle
    Peninsula Medical School, University of Exeter, Exeter, UK
    Pharmacoeconomics 29:1-15. 2011
  7. doi request reprint Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Peninsular College of Medicine and Dentistry, University of Exeter, Exeter, UK
    Value Health 13:885-92. 2010
  8. doi request reprint Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Peninsula Medical School, University of Exeter, Exeter, United Kingdom
    Med Decis Making 30:426-37. 2010
  9. doi request reprint Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma
    Martin Hoyle
    Peninsula Medical School, University of Plymouth, Plymouth, UK
    Value Health 13:55-60. 2010
  10. doi request reprint Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma
    Martin Hoyle
    Peninsula Medical School, University of Plymouth, Plymouth, UK
    Value Health 13:61-8. 2010

Detail Information

Publications16

  1. ncbi request reprint Future drug prices and cost-effectiveness analyses
    Martin Hoyle
    Peninsula Medical School, Peninsula Technology Assessment Group PenTAG, Universities of Plymouth and Exeter, Exeter, UK
    Pharmacoeconomics 26:589-602. 2008
    ..Furthermore, in the sensitivity analysis, the real prices of the new and comparator drugs should be deflated by 2% per year as a proxy for inflation...
  2. doi request reprint Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Medical School, University of Exeter, Exeter, UK
    Value Health 16:288-96. 2013
    ....
  3. doi request reprint Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia
    Martin Hoyle
    Peninsular College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom
    Value Health 14:1057-67. 2011
    ....
  4. doi request reprint Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
    M Hoyle
    PenTAG, Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth, UK
    Health Technol Assess 15:61-7. 2011
    ..The final appraisal determination was issued by NICE in September 2010 (www.nice.org.uk/nicemedia/live/12264/50758/50758.pdf)...
  5. pmc Improved curve fits to summary survival data: application to economic evaluation of health technologies
    Martin W Hoyle
    Peninsula College of Medicine and Dentistry, Veysey Building, Salmon Pool Lane, Exeter, EX2 4SG, UK
    BMC Med Res Methodol 11:139. 2011
    ..Instead, it is common to fit curves to summary Kaplan-Meier graphs, either by regression or by least squares. Here, a more accurate method of fitting survival curves to summary survival data is described...
  6. doi request reprint Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis
    Martin Hoyle
    Peninsula Medical School, University of Exeter, Exeter, UK
    Pharmacoeconomics 29:1-15. 2011
    ..The methodology is very simple to implement. It is suggested that the model should be parameterized for other countries...
  7. doi request reprint Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Peninsular College of Medicine and Dentistry, University of Exeter, Exeter, UK
    Value Health 13:885-92. 2010
    ..Here, I quantify and analyze the historical lifetimes of drugs in England. I then apply this information to inform the value of further research and the cost-effectiveness of health technologies...
  8. doi request reprint Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts
    Martin Hoyle
    Peninsula Technology Assessment Group PenTAG, Peninsula Medical School, University of Exeter, Exeter, United Kingdom
    Med Decis Making 30:426-37. 2010
    ..Most health technology economic evaluations simulate only the prevalent cohort or the next incident cohort of patients. They therefore do not capture all future patient-related benefits and costs...
  9. doi request reprint Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma
    Martin Hoyle
    Peninsula Medical School, University of Plymouth, Plymouth, UK
    Value Health 13:55-60. 2010
    ..To estimate the cost-effectiveness of sorafenib (Nexavar, Bayer, Leverkusen, Germany) versus best supportive care (BSC) for second-line treatment of advanced renal cell carcinoma from the perspective of the UK National Health Service...
  10. doi request reprint Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma
    Martin Hoyle
    Peninsula Medical School, University of Plymouth, Plymouth, UK
    Value Health 13:61-8. 2010
    ..To estimate the cost-effectiveness of temsirolimus compared to interferon-alpha for first line treatment of patients with advanced, poor prognosis renal cell carcinoma, from the perspective of the UK National Health Service...
  11. doi request reprint Evolution of a cost-utility model of donepezil for Alzheimer's disease
    Jaime L Peters
    PenTAG, University of Exeter, UK
    Int J Technol Assess Health Care 29:147-54. 2013
    ....
  12. doi request reprint Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model
    Christopher Hyde
    PCMD, University of Exeter, PenTAG, Veysey Building Salmon Pool Lane, Exeter, Devon EX2 4SG, UK
    Age Ageing 42:14-20. 2013
    ..Introduction: in 2007 the National Institute of Health and Clinical Excellence (NICE) restricted the use of acetylcholinesterase inhibitors and memantine...
  13. ncbi request reprint Effect of pollinator abundance on self-fertilization and gene flow: application to GM Canola
    Martin Hoyle
    PenTAG, Peninsula Medical School, University of Plymouth, Noy Scott House, Barrack Road, Exeter EX2 5DW, United Kingdom
    Ecol Appl 17:2123-35. 2007
    ..Our results therefore suggest that the wind, not bees, is the main vector of long-distance gene flow in canola...
  14. ncbi request reprint The effect of wind direction on cross-pollination in wind-pollinated GM crops
    Martin Hoyle
    School of Biosciences, University of Exeter, Exeter EX4 4PS, UK
    Ecol Appl 17:1234-43. 2007
    ..Additionally, we suggest suitable time lags between peak flowering in adjacent fields that could be introduced to reduce cross-pollination to a specified level...
  15. ncbi request reprint A search theory model of patch-to-patch forager movement with application to pollinator-mediated gene flow
    Martin Hoyle
    School of Biosciences, University of Exeter, Exeter EX4 4PS, UK
    J Theor Biol 248:154-63. 2007
    ....
  16. pmc Causes of the species-area relationship by trophic level in a field-based microecosystem
    Martin Hoyle
    Department of Life and Environmental Sciences, University of Nottingham, Nottingham NG7 2RD, UK
    Proc Biol Sci 271:1159-64. 2004
    ..This is the first attempt, to my knowledge, to quantify the causes of the species-area relationship...